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The aim of the study was to investigate the DNA polymorphic genotype in MMP-2 promoter gene as a potential candidate region
for the development of the cutaneous T-cell lymphoma (CTCL) and/or its progression. A total of 89 Czech patients with CTCL
(including 23 patients with large plaque parapsoriasis) were compared to 198 controls of similar age and sex distribution, without
personal or family history of chronic skin diseases and without personal history of malignancy. The three selected polymorphisms
in the promoter of MMP-2 gene (−1575G/A, −1306C/T, and −790T/G) were determined using the PCR-based methodology with
RFLP. In our cohort, the associated GGCCTT MMP-2 promoter genotype was highly signiﬁcantly more frequent in CTCL-Ia stage
patients compared to patients with parapsoriasis, the tests having high sensitivity and speciﬁcity (78%, 83%, resp.). To conclude,
use of associated MMP-2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with
parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design,
and prognosis of this serious condition in the early stages.
1.Introduction
The cutaneous T-cell lymphoma is characterized by skin
inﬁltrating and/or circulating malignant cells displaying a
CD4+CD7− phenotype in the majority of cases [1]. CD4+ T
lymphocytes from a nonmalignant cloned human T-cell line
have been recently reported to produce a 92-kD gelatinase
(MMP 9). Apart from production of this 92-kD gelatinase,
malignant T-cell clones were reported to produce reduced
amounts of a 72kD gelatinase (MMP 2) [1].
Generally, expression and production of matrix met-
alloproteinases (MMPs) is associated with advanced-stage
tumour disease and MMPs are known to contribute to
tumour progression, invasion, and formation of metastases.
In patients with mycosis fungoides (MF), the expression of
MMP-2andMMP-9mRNAswasobservedtobesigniﬁcantly
upregulated in advanced stages, the expression of either
MMP-2 and/or MMP-9 mRNAs consistently rising with
advancing disease [2]. V. Apart from their production in MF
cells, the MMP-2 and/or MMP-9 mRNAs were found to be
expressed by some stromal cell populations (microvascular
endothelial cells, ﬁbroblasts, macrophages), which might be
suggestive of the involvement of these cells in the process of
tumor invasion. Only weak positivity of the MMP-2 mRNA
in microvascular endothelial cells wasreported in the control
skin samples [2–4], which might be of some importance for
further establishment of MMP-2 as a novel clinical marker.
The large repertoire of cells inside the tumour tissue
seems to be involved in the process of upregulation of MMP-
2 expression level during CTCL progression. Therefore, all
the factors inﬂuencing MMP-2 gene expression, especially
transcription factors, can participate in the process of
development of CTCL. The rationale for the study is that
variability in the MMP-2 gene promoter can have direct
impact on binding of transcription factors, for example, by
changing the aﬃnity for given proteins.
MMP-2 gene is located at 16q13. Based on results of
comparativegenomichybridizationandtranscriptomicdata,
the 16p region was identiﬁed as a target region for CTCL-
associated gene aberrations [5].2 Journal of Biomedicine and Biotechnology
There is a general consensus that MMP-mediated pro-
teolysis is essential for cancer progression and that certain
MMPsrepresentimportanttargetsforintervention,eﬀective,
and selective inhibition, however, pharmacological interven-
tion in terms of these MMPs remains a major challenge in
drug development [6, 7]. Interindividual variability in the
MMP genes might also play an important part in inves-
tigation of pharmacogenetic aspects of the MMP-modu-
lated therapy.
The aim of the study was to associate DNA polymorphic
genotypes in MMP-2 promoter gene with general risk for
CTCL development and/or its severity (stages).
2.MaterialandMethods
2.1. Subjects. A total of 89 patients with CTCL (including
23 patients with large plaque parapsoriasis), diagnosed and
treated at the 1st Department of Dermatology of St Ann’s
Faculty Hospital Brno (55 men and 34 women, median age
62y, range 26–101 years) were compared to 198 controls
(133 men and 65 women, median age 58y, age range 26–80)
without personal or family history of chronic skin diseases
and without personal history of malignancy.
The patients with CTCL were classiﬁed according to
Tumor Node Metastasis (TNM) Classiﬁcation for Cutaneous
T-CellLymphomaaccordingtoKashani-Sabetetal.2001[8].
In CTCL men, 50% were treated by topical steroids
(20%incombinationwithphototherapy,2%withretinoids).
The CTCL women were treated by topical steroids in 55%
(23%incombinationwithphototherapy,5%withretinoids).
Phototherapy was indicated in 51% of CTCL men and in
51% of CTCL women.
This study was approved by the Committee for Ethics
of Medical Experiments on Human Subjects, Faculty of
Medicine, Masaryk University, Brno (no. 64/93, 1993) and
was performed in adherence to the Declaration of Helsinki
Guidelines. Participants gave their written informed consent
which has been archived.
2.2. Genotyping. Genomic DNA was isolated from periph-
eral leukocytes by a standard technique using proteinase K.
Three MMP-2 promoter polymorphisms (−1575G/A,
−1306C/T and −790T/G) were identiﬁed by PCR method
and restriction analysis according to standard protocols.
Polymorphism −1575G/A MMP-2 was detected by PCR
using sense 5 -ACT GAC TCT GGA AAG TCA GAG CA-
3  and antisense 5 -GGC ACA GGG TGA GGG GAT GG-
3  primers with a PCR product of 269bp. After restriction
analysis with Tsp45I (↓GT G/C AC, New England Biolabs
Inc., USA) at 65
◦C for 4h, three genotypes could be
distinguished in UV light at 2% agarose Serva with ethidium
bromide: GG (113 and 156bp), GA (113, 156 and 269bp),
and AA (269bp).
Polymorphism −1306C/T MMP-2 was detected by PCR
using sense 5 -CTT CCT AGG CTG GTC CTT ACT GA-
3  and antisense 5 -CTG AGA CCT GAA GAG CTA AAG-
AGC T-3  primers with a PCR product of 193bp. After
restriction analysis with XspI (C↓TAG, Takara, Japan) at
37
◦C for 4h, three genotypes could be distinguished: CC
(188bp), CT (188, 162 and 26bp), and TT (162 and 26bp).
Polymorphism −790T/G MMP-2 was detected by PCR
using sense 5 -GGG TCT TTG TGA CCT CGA TC-3 
and antisense 5 -GGT AAA ATG AGG CTG AGA CCT G-
3  primers with a PCR product of 118bp. After restriction
analysis with PvuI (CGAT/CG, MBI Fermentas, Lithuania)
at 37
◦C for 3h, three genotypes could be observed in UV
light at 3% Metaphor agarose with ethidium bromide: TT
(118bp), GT (118 and 19+99bp), and GG (19+99bp) [9].
2.3. Statistical Analyses. In all investigated cohorts, distribu-
tions ofgenotype andallelicfrequenciesandtheirdiﬀerences
were calculated using χ2 tests. Consistency of genotype
frequencies with the Hardy-Weinberg equilibrium was tested
using χ2 test on a contingency table of observed versus
predicted genotype frequencies.
Odds ratio (OR) and 95% conﬁdence interval were
calculated to estimate the risks related to detected poly-
morphisms. To calculate the signiﬁcance of OR, Fisher’s
exact test was used. Sensitivity and speciﬁty of results were
calculated by Clinical Calculator 1 (http://faculty.vassar.edu/
lowry/clin1.html). The Holm’s test was employed for appro-
priate correction to multiple comparisons. The program
package Statistica v. 8.0 (Statsoft Inc., Tulsa, OK) was used.
3. Results
3.1. Case-Control Study. No signiﬁcant diﬀerences in case-
control analysis, neither in genotype distributions or allelic
frequencies of all investigated MMP-2 polymorphisms were
observed, when performing the analyses separately for the
individualpolymorphisms(Table 1).Similarly,nosigniﬁcant
diﬀerences were observed between men and women, neither
in the CTCL nor control cohort (data not shown).
All the three polymorphisms were found to be in
linkage disequilibrium. When investigating the frequency of
associatedgenotype(GGCCTT),thatis,themostfrequentin
the general population, no diﬀerences between patients with
CTCL and control subjects were observed (37 patients with
GGCCTT/52patientswithothergenotypeversus100control
subjects with GGCCTT/98 control subjects with other geno-
type,P = .101).Similarly,nodiﬀerencesinthefrequenciesof
GGCCTTgenotypewereobservedbetweenmenandwomen,
neither in the CTCL cohort nor the controls.
3.2. Case-Case Study. However, highly signiﬁcant diﬀerences
were observed when comparing the frequencies of the
GGCCTT associated MMP-2 genotypes between the speciﬁc
stages of CTCL. Based on our results, the GGCCTT MMP-
2 promoter genotype is signiﬁcantly more frequent in
CTCL-Ia stage patients compared to all other CTCL groups
including parapsoriasis (Table 2). All comparisons retained
their signiﬁcance after appropriate correction for multiple
comparisons (Pcorr). The GGCCTT genotype was observed
to be the most sensitive and speciﬁc marker to distinguish
between CTCL patients with stage IA and the patientsJournal of Biomedicine and Biotechnology 3
Table 1: Three promoter MMP-2 gene polymorphisms: patients with CTCL versus control subjects.
−1575/G
Genotypes and alleles GG (%) GA (%) AA (%) Pg GAPa
CTCL (N = 89) 48 (54) 37 (42) 4 (4) 0.931 0.747 0.253 0.804
Controls (N = 198) 105 (53) 82 (41) 11 (6) 0.737 0.263
−1306 C/T
Genotypes and alleles CC (%) CT (%) TT (%)
0.492
CT
0.853 CTCL (N = 89) 46 (52) 41 (46) 2 (2) 0.747 0.253
Controls (N = 198) 105 (53) 83 (42) 10 (5) 0.740 0.260
−790 T/G
Genotypes and alleles TT (%) TG (%) GG (%)
0.091
TG
0.258 CTCL (N = 89) 46 (52) 39 (44) 4 (4) 0.736 0.264
Controls (N = 198) 100 (51) 73 (37) 25 (12) 0.689 0.311
Pg = P-value of a diﬀerence in genotype distribution
Pa = P-value of a diﬀerence in allelic frequencies.
Table 2: Risk for GGCCTT associated genotype in MMP-2 gene promoter in diﬀerent CTCL stages compared to CTCL-Ia.




∗ (N = 23) 4 (17) 19 (83) 0.07 (0.01−0.28) .00004 (0.0002)
CTCL-Ia (N = 23) 18 (77) 5 (23)
CTCL-Ib (N = 24) 10 (42) 14 (58) 0.10 (0.06−0.71) .01 (0.02)
CTCL II (N = 11) 3 (25) 8 (75) 0.10 (0.02−0.55) .007 (0.03)
CTCL III+IV (N = 8) 2 (30) 6 (70) 0.09 (0.01−0.61) .01 (0.02)
Controls (N = 198) 100 (51) 98 (49) 0.28 (0.10−0.79) .009 (0.03)
∗LPP- large plaque parapsoriasis
∗∗Odds ratio for GGCCTT in any group compared to CTCL-Ia (95% conﬁdential interval)
∗∗∗Pcorr = P-value corrected for multiple comparison.
with parapsoriasis (sensitivity is 78%, 95% CI = 56–92%;
speciﬁty is 83%, 95% CI = 60–94%).
When evaluating the risk of GGCCTT MMP-2 geno-
type for development of parapsoriasis, we observed higher
frequencies of the GGCCTT genotype in all other CTCL
groups as well as in control subjects (Table 3). In this case,
the diﬀerences were signiﬁcant when comparing the CTCL-
Ia patients and the control subjects.
4. Discussion
Early diagnosis of CTCL is an extremely important point
for eﬃcient decision-making in the treatment of CTCL.
However, there is no generally accepted consensus on the
range of criteria that should be employed to achieve as early
diagnosis of the disease as possible [10]. The diﬀerential
diagnosis between early stages of mycosis fungoides and
large plaque parapsoriasis (both considered a form of CTCL)
can be often diﬃcult, especially when being based merely
on evaluation of clinical and histological parameters [11].
Therefore, there is a strong need for novel markers that
would make the earlier diagnosis of the disease possible; for
example, CD13 (aminopeptidase N) was recently identiﬁed
as an early prognostic factor in CTCL [12]. Based on
our results, the variability of the MMP-2 promoter region
might act as potential biomarker of diﬀerent CTCL stages,
especially as for the CTCL stage IA and large plaque
parapsoriasis. This is to the best of our knowledge the
ﬁrst study of given SNPs in MMP-2 gene on CTCL cases,
which was carried out on a highly static population of the
SouthMoravia,ofaCentral-EuropeanCaucasianorigin.Not
surprisingly, it will be necessary to replicate the results of the
study on larger population samples of diﬀerent ethnicity to
achieve a ﬁnal conclusion of the importance and signiﬁcance
of the MMP-2 gene variability in CTCL.
Taking into account the structure of DNA in the
given locus, the GGCCTT genotype in the promoter of
MMP-2 gene should have a high transcription rate. Two
functional SNPs in vitro in the MMP-2 promoter were
recently investigated: −1575G to A, which alters binding
of oestrogen receptor [13], and −1306C to T, which alters
binding of Sp-1. The C, but not T allele of −1306C/T
MMP-2 polymorphism contains an Sp1 motif (CCAACC
box), therefore displaying strikingly higher promoter activity
in vitro [14]. The transcription factor Sp1 is a DNA-
binding protein which interacts with a variety of gene
promoters containing GC-box elements. The factor regulates
the expression of a number of genes participating in multiple
aspects of tumorigenesis, such as angiogenesis, cell growth,
and apoptosis resistance. The Sp1 levels in untransformed4 Journal of Biomedicine and Biotechnology
Table 3: Risk for GGCCTT associated genotype in MMP-2 gene promoter in diﬀerent CTCL stages compared to parapsoriasis.




∗ (N = 23) 4 (17) 19 (83)
CTCL-Ia (N = 23) 18 (77) 5 (23) 17.10 (3.95−73.95) .00004 (0.0002)
CTCL-Ib (N = 24) 10 (42) 14 (58) 3.39 (0.88−13.08) .07
CTCL II (N = 11) 3 (25) 8 (75) 1.78 (0.32−9.85) .400
CTCL III+IV (N = 8) 2 (30) 6 (70) 1.58 (0.23−10.90) .497
Controls (N = 198) 100 (51) 98 (49) 4.85 (1.59−14.76) .002 (0.008)
∗LPP - large plaque parapsoriasis
∗∗Odds ratio for GGCCTT in any group compared to LPP (95% conﬁdential interval)
∗∗∗Pcorr =P-value corrected for multiple comparison.
cells must be tightly regulated as Sp1 overexpression leads
to the induction of apoptosis. Recently, Sp1 has been shown
to be overexpressed in a number of human cancers, whereas
its overexpression is supposed to contribute to malignant
transformation [15].
Furthermore, in silico, three transcription factors could
be found in the DNA sequence including the T allele
of −790G/T MMP-2 polymorphism: KLF4 (Kruppel-like
factor 4, S8 and Evi1-ectopic viral integration site 1 encoded
factor(according to the Transfac Matrix Table (MatInspector
V2.2). KLF4 represents the essential transcription factor
which is critical and selective for establishment of the proper
barrierfunctionoftheskin[16].KLF4wasprovedtointeract
withbeta-cateninandtoinhibitWntsignalling[17].MMP-2
seems to be a Wnt target gene because two TCF sites typical
for this gene were identiﬁed in MMP-2 gene promoter, inter-
estingly in a close vicinity of the −790G/T polymorphism
(at −861 and −804 positions). Wnt signalling was observed
not only to induce expression of matrix metalloproteinase
2, but also to regulate transmigration of T cells [18]. Wnts
probably induces a T-cell phenotype capable of migration
throughcollagen[18].Thisabilityiscrucialforextravasation
of T cells, which is not observed in parapsoriasis as a
rule. Finally, this could explain the observed diﬀerence in
variability of promoter of MMP-2 gene between the patients
withparapsoriasisandCTCL-Iastage.Lastbutnotleast,Evi1
is a highly conserved transcription factor that was shown
to upregulate cell proliferation, to impair cell diﬀerentiation
and also to induce malignant transformation [19].
To conclude, the frequency of the GGCCTT MMP-
2 genotype was the lowest in the group of patients with
parapsoriasis, when compared to the control subjects. On
the other hand, the eﬃcient form of MMP-2 promoter
seems to be associated with CTCl Ia stage. We propose an
idea that the detection of MMP-2 promoter polymorphism
might contribute to resolution between speciﬁc stages in the
framework of CTCL cohort, that is, between the patients
with parapsoriasis and CTCL Ia stage, whereas the test has
satisfactory sensitivity and speciﬁty. From the clinical point
of view, the GGCCTT MMP-2 genotype can be considered
a potential DNA marker that might be employed to assist
in clinical resolution between CTCL Ia and parapsoriasis.
Our study continues in newly diagnosed patients with
large plaque parapsoriasis and with all stages of CTCL,
examination of MMP-2 gene expression will be performed
from bioptic skin lesion samples by RT-PCR method. This
enables to evaluate the actual functional association between
the promoter MMP-2 genotype and MMP-2 expression
in the skin of patients with a diﬀerent stage of CTCL.
Deﬁnitely, further studies on larger population sample are
necessary that could substantially complete possibilities
of clinical diagnostics, individualize therapy design, and
improve prognosis of the serious disease with respect to
variability of MMP-2 gene.
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